EVALUATING THE COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK

被引：1
|
作者：
Ashley, D. [1 ]
Vega, G. [1 ]
Hunt, B. [2 ]
Valentine, W. J. [2 ]
机构：
[1] Novo Nordisk Ltd, Gatwick, England
[2] Ossian Hlth Econ & Commun, Basel, Switzerland
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2093
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB54
引用
收藏
页码：A606 / A606
页数：1
相关论文
共 50 条
  • [1] Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
    Hunt, Barnaby
    Ye, Qing
    Valentine, William J.
    Ashley, Donna
    DIABETES THERAPY, 2017, 8 (01) : 129 - 147
  • [2] Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom
    Barnaby Hunt
    Qing Ye
    William J. Valentine
    Donna Ashley
    Diabetes Therapy, 2017, 8 : 129 - 147
  • [3] Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
    Margarita Capel
    Andreea Ciudin
    María Mareque
    Raquel María Rodríguez-Rincón
    Susana Simón
    Itziar Oyagüez
    PharmacoEconomics - Open, 2020, 4 : 277 - 286
  • [4] Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
    Capel, Margarita
    Ciudin, Andreea
    Mareque, Maria
    Maria Rodriguez-Rincon, Raquel
    Simon, Susana
    Oyaguez, Itziar
    PHARMACOECONOMICS-OPEN, 2020, 4 (02) : 277 - 286
  • [5] COST-EFFECTIVENESS ANALYSIS OF EXENATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Capel, M.
    Ciudin, A.
    Mareque, M.
    Rodriguez, R. M.
    Oyaguez, I
    VALUE IN HEALTH, 2018, 21 : S129 - S129
  • [6] The GLP-1 Receptor Agonists Are Cost-Effective for the Treatment of Type 2 Diabetes
    Plodkowski, Raymond
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (04): : 187 - 188
  • [7] GLP-1 receptor agonists for type 2 diabetes
    De Block, Christophe E. M.
    Van Gaal, Luc F.
    LANCET, 2009, 374 (9683): : 4 - 6
  • [8] Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
    Chen-Yi Yang
    Ying-Ren Chen
    Huang-Tz Ou
    Shihchen Kuo
    Cardiovascular Diabetology, 20
  • [9] Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review
    Yang, Chen-Yi
    Chen, Ying-Ren
    Ou, Huang-Tz
    Kuo, Shihchen
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [10] GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
    Juris J. Meier
    Nature Reviews Endocrinology, 2012, 8 : 728 - 742
12345